NeoImmuneTech Past Earnings Performance
Past criteria checks 0/6
NeoImmuneTech's earnings have been declining at an average annual rate of -18.9%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
-18.9%
Earnings growth rate
-15.0%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | n/a |
| Return on equity | -79.2% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How NeoImmuneTech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -46,564 | 44,242 | 0 |
| 31 Mar 24 | 0 | -53,043 | 51,227 | 0 |
| 31 Dec 23 | 0 | -53,405 | 52,597 | 0 |
| 30 Sep 23 | 0 | -44,164 | 74,305 | -29,399 |
| 30 Jun 23 | 0 | -50,484 | 74,121 | -26,532 |
| 31 Mar 23 | 0 | -56,634 | 51,958 | 0 |
| 31 Dec 22 | 0 | -60,406 | 55,326 | 0 |
| 30 Sep 22 | 0 | -72,829 | 24,872 | 40,017 |
| 30 Jun 22 | 0 | -65,982 | 34,465 | 26,532 |
| 31 Mar 22 | 0 | -57,344 | 54,368 | 0 |
| 31 Dec 21 | 0 | -52,482 | 50,090 | 0 |
| 30 Sep 21 | 0 | -48,211 | 24,669 | 22,704 |
| 30 Jun 21 | 0 | -43,086 | 19,769 | 22,704 |
| 31 Mar 21 | 0 | -35,855 | 13,198 | 22,704 |
| 31 Dec 20 | 0 | -30,456 | 8,134 | 22,704 |
| 30 Sep 20 | 0 | -25,606 | 22,515 | 3,359 |
| 30 Jun 20 | 0 | -22,042 | 16,838 | 5,899 |
| 31 Mar 20 | 0 | -17,481 | 11,121 | 7,246 |
| 31 Dec 19 | 0 | -14,198 | 6,849 | 8,592 |
Quality Earnings: A950220 is currently unprofitable.
Growing Profit Margin: A950220 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A950220 is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.
Accelerating Growth: Unable to compare A950220's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A950220 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).
Return on Equity
High ROE: A950220 has a negative Return on Equity (-79.16%), as it is currently unprofitable.